There are several types of breast cancer, each with distinct biological characteristics. These include hormone receptor-positive (HR+), HER2-positive, and triple-negative breast cancer (TNBC). The disease can originate in different parts of the breast, such as the ducts or lobules, and may spread to lymph nodes or distant organs². A combination of genetic, hormonal, and environmental factors influences its development.

Understanding the physiopathology of breast cancer involves exploring how normal breast cells transform into malignant ones. This process is driven by mutations in genes like BRCA1, BRCA2, and PIK3CA, as well as disruptions in signaling pathways that control cell growth and repair. Epidemiological studies show that age, family history, reproductive history, and lifestyle factors such as alcohol consumption and obesity contribute to risk³.

As we move through 2025, researchers are uncovering new layers of complexity in breast cancer biology and treatment. Here’s a look at some of the most discussed topics in the field.

Molecular and cellular insights

One of the most exciting areas of progress is our growing understanding of tumor heterogeneity. Breast tumors are not uniform; they consist of diverse cell populations with different genetic and phenotypic profiles. This diversity can influence how tumors respond to treatment and how they evolve over time⁴.

Single-cell sequencing has become a powerful tool for dissecting this complexity. It allows scientists to analyze gene expression at the level of individual cells, revealing rare subpopulations that may drive resistance or metastasis⁵. Spatial transcriptomics adds another layer by mapping gene activity within the tissue context, helping researchers understand how cancer cells interact with their microenvironment⁶.

Another area gaining attention is metastatic dormancy. Some breast cancer cells can remain inactive in distant organs for years before reactivating. Studies are now focusing on the signals that keep these cells dormant and what triggers their reawakening. This could lead to strategies that prevent recurrence by targeting dormant cells before they become active again⁷.

Targeted therapies and antibody-drug conjugates (ADCs)

Targeted therapies continue to evolve, especially for HER2-positive breast cancer. Trastuzumab-Deruxtecan (T-DXd), an antibody-drug conjugate, has shown promise in treating patients with low HER2 expression, expanding its potential use beyond traditional HER2-positive cases⁸.

New ADCs are also being developed to target proteins like Nectin-4 and TROP2. These therapies combine a monoclonal antibody with a cytotoxic drug, delivering treatment directly to cancer cells while sparing healthy tissue. Multi-payload strategies are being explored to overcome resistance and address tumor heterogeneity more effectively⁹.

These innovations are particularly relevant for patients with advanced or treatment-resistant disease, offering new options where standard therapies may fall short.

Biomarkers and precision medicine

Precision medicine is remodeling how we diagnose and treat breast cancer. Biomarkers—molecular indicators of disease—are central to this approach. They help identify which patients are likely to benefit from specific treatments and monitor how well they work¹⁰.

Liquid biopsies are emerging as a non-invasive way to detect and track cancer. By analyzing circulating tumor DNA (ctDNA) in the blood, clinicians can gain insights into tumor mutations, treatment response, and early signs of relapse. This approach is especially useful for patients who cannot undergo repeated tissue biopsies¹¹.

Artificial intelligence (AI) is also playing a growing role in biomarker discovery. Machine learning algorithms can analyze large datasets to identify patterns that might be missed by traditional methods. This could lead to more accurate predictions of treatment outcomes and better patient stratification in clinical trials¹².

Prevention and risk reduction

While treatment advances are important, prevention remains a key focus. Genetic screening is helping identify individuals at high risk of breast cancer, particularly those with BRCA1 or BRCA2 mutations¹³. These individuals can benefit from enhanced surveillance or preventive measures such as prophylactic surgery.

Researchers are also refining risk prediction models by incorporating genetic, hormonal, and lifestyle factors. These models can guide personalized prevention strategies and inform public health policies.

Lifestyle interventions are under investigation as well. Studies suggest that maintaining a healthy weight, limiting alcohol intake, and staying physically active may reduce breast cancer risk. Environmental exposures, such as endocrine-disrupting chemicals, are also being studied for their potential role in disease development¹⁴.

Chemoprevention—using drugs to reduce cancer risk—is another area of interest. Agents like tamoxifen and raloxifene have shown efficacy in specific populations, and new compounds are being tested for broader use¹⁵.

Key considerations

As breast cancer research progresses, collaboration across disciplines will be imperative. Integrating molecular biology, data science, clinical oncology, and patient advocacy can accelerate progress and ensure that innovations translate into real-world benefits.

Researchers should also consider the importance of diversity in clinical trials. Ensuring that studies include participants from different backgrounds can help uncover variations in disease biology and treatment response, leading to more equitable care¹⁶.

Finally, as new technologies emerge, ethical considerations must remain front and center. This includes protecting patient privacy in genomic studies, ensuring informed consent, and addressing disparities in access to advanced diagnostics and therapies.

Breast cancer research in 2025 is marked by a deeper understanding of biology, more precise treatments, and a growing emphasis on prevention. By staying curious, collaborative, and patient-focused, the scientific community can continue to make meaningful strides in the fight against this complex disease.

References

1.    Sung, H.  et al.  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.  CA Cancer J. Clin.  71, 209–249 (2021).

2.    Orrantia-Borunda, E.  et al.  Subtypes of Breast Cancer. In: Mayrovitz, H.N. (ed.)  Breast Cancer  [Internet]. Brisbane (AU): Exon Publications; Chapter 3 (2022). Available from: https://www.ncbi.nlm.nih.gov/books/NBK583808/

3.    Feng, Y.  et al.  Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.  Genes Dis.  5, 77–106 (2018).

4.    Polyak, K. Heterogeneity in breast cancer.  J. Clin. Invest.  121, 3786–3788 (2011).

5.    Xiang, L.  et al.  Single-cell RNA-sequencing: Opening new horizons for breast cancer research.  Int. J. Mol. Sci.  25, 9482 (2024).

6.    Janesick, A.  et al.  High resolution mapping of the tumor microenvironment using integrated single-cell, spatial and in situ analysis.  Nat. Commun.  14, 8353 (2023).

7.    Park, S.-Y. & Nam, J.-S. The force awakens: metastatic dormant cancer cells.  Exp. Mol. Med.  52, 569–581 (2020).

8.    Larose, É.A.  et al.  Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing.  Cancer Drug Resist.  8, 11 (2025).

9.    Shastry, M.  et al.  Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.  Breast  66, 169–177 (2022).

10. Zhou, Y.  et al.  Tumor biomarkers for diagnosis, prognosis and targeted therapy.  Signal Transduct. Target. Ther.  9, 132 (2024).

11. Ma, L.  et al.  Liquid biopsy in cancer: current status, challenges and future prospects.  Signal Transduct. Target. Ther.  9, 336 (2024).

12. Ahn, J.S.  et al.  Artificial intelligence in breast cancer diagnosis and personalized medicine.  J. Breast Cancer  26, 405–435 (2023).

13. Petrucelli, N., Daly, M.B. & Pal, T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam, M.P.  et al.  (eds.)  GeneReviews®  [Internet]. Seattle (WA): University of Washington, Seattle; (1998 [updated 2025]). Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/

14. Marino, P.  et al.  Healthy lifestyle and cancer risk: Modifiable risk factors to prevent cancer.  Nutrients  16, 800 (2024).

15. Manna, E.D.F.  et al.  Chemoprevention and lifestyle modifications for risk reduction in sporadic and hereditary breast cancer.  Healthcare (Basel)  11, 2360 (2023).

16. Gross, A.S.  et al.  Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response.  Br. J. Clin. Pharmacol.  88, 2700–2717 (2022).